Literature DB >> 19908072

Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation.

Jinyu Li1, Xiaolei Zhu, Cao Yang, Rongwei Shi.   

Abstract

Human serum albumin (HSA), the most abundant protein found in blood plasma, transports many drugs and ligands in the circulatory system. The drug binding ability of HSA strongly influences free drug concentrations in plasma, and is directly related to the effectiveness of clinical therapy. In current work, binding of HSA to angiotensin II receptor blockers (ARBs) are investigated using docking and molecular dynamics (MD) simulations. Docking results demonstrate that the main HSA-ARB binding site is subdomain IIIA of HSA. Simulation results reveal clearly how HSA binds with valsartan and telmisartan. Interestingly, electrostatic interactions appear to be more important than hydrophobic interactions in stabilizing binding of valsartan to HSA, and vice versa for HSA-telmisartan. The molecular distance between HSA Trp214 (donor) and the drug (acceptor) can be measured by fluorescence resonance energy transfer (FRET) in experimental studies. The average distances between Trp-214 and ARBs are estimated here based on our MD simulations, which could be valuable to future FRET studies. This work will be useful in the design of new ARB drugs with desired HSA binding affinity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19908072     DOI: 10.1007/s00894-009-0612-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  43 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.

Authors:  S Aslam; T Santha; A Leone; C Wilcox
Journal:  Kidney Int       Date:  2006-10-25       Impact factor: 10.612

3.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

4.  Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids.

Authors:  Shin-Ichi Fujiwara; Takashi Amisaki
Journal:  Proteins       Date:  2006-08-15

Review 5.  Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Authors:  Z H Israili
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

6.  Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.

Authors:  K Katayama; S Nomura; H Ishikawa; T Murata; S Koyabu; T Nakano
Journal:  Kidney Int       Date:  2006-05-17       Impact factor: 10.612

7.  Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.

Authors:  D M Colussi; C Parisot; M L Rossolino; L A Brunner; G Y Lefèvre
Journal:  J Clin Pharmacol       Date:  1997-03       Impact factor: 3.126

8.  Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity.

Authors:  Naila Ahmed; Darin Dobler; Mark Dean; Paul J Thornalley
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Savita Shrivastava; Murtaza Hassanali; Paul Stothard; Zhan Chang; Jennifer Woolsey
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  4 in total

1.  Molecular dynamics simulation studies of betulinic acid with human serum albumin.

Authors:  Chandramouli Malleda; Navjeet Ahalawat; Mahesh Gokara; Rajagopal Subramanyam
Journal:  J Mol Model       Date:  2011-11-11       Impact factor: 1.810

2.  Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors.

Authors:  Karunakar Tanneeru; Lalitha Guruprasad
Journal:  J Mol Model       Date:  2011-07-30       Impact factor: 1.810

3.  Computational studies of the binding mechanisms of fullerenes to human serum albumin.

Authors:  Jinyu Li; Lizhi Jiang; Xiaolei Zhu
Journal:  J Mol Model       Date:  2015-06-21       Impact factor: 1.810

4.  Spectroscopic and molecular docking studies for characterizing binding mechanism and conformational changes of human serum albumin upon interaction with Telmisartan.

Authors:  Mohammed Al Bratty
Journal:  Saudi Pharm J       Date:  2020-05-06       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.